HANGZHOU TIGERMED CONSULTING (300347) Q3 2025 earnings summary

Executive summary

• Net profit attributable to shareholders for Q3 surged 98.73% year-over-year to ¥637.10 million, with basic and diluted EPS both at ¥0.74, up 100% from the same period last year.

• Year-to-date revenue reached ¥5.03 billion, a slight decrease of 0.82% year-over-year, while net profit attributable to shareholders rose 25.45% to ¥1.02 billion.

• Non-recurring gains, mainly from investment income and fair value changes, significantly boosted quarterly results.

Financial highlights

• Q3 revenue: ¥1.78 billion, up 3.86% year-over-year; year-to-date revenue: ¥5.03 billion, down 0.82%.

• Q3 net profit attributable to shareholders: ¥637.10 million, up 98.73% year-over-year; year-to-date: ¥1.02 billion, up 25.45%.

• Net profit excluding non-recurring items dropped 54.25% in Q3 and 63.46% year-to-date.

• Operating cash flow for Q3: ¥739.56 million, up 27.78% year-over-year.

• Total assets at period end: ¥28.78 billion, up 0.39% from year-end; equity attributable to shareholders: ¥21.18 billion, up 2.45%.

Outlook and guidance

• Management approved the sale of a significant equity stake in an associate, reflecting a strategic shift and capital reallocation.